Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Reliant Pharmaceuticals

Reliant Pharmaceuticals
1999 FOUNDED
M&A STATUS
901-1000 EMPLOYEES
IPO LATEST DEAL TYPE (Cancelled)
$305M LATEST DEAL AMOUNT
Description

Developer of cardiovascular therapies. The company acquires and develops branded pharmaceutical products, as well as potential pharmaceutical products in mid- to late-stage clinical development for drug delivery technologies and formulation advancements.

Formerly Known As
Bay Star Pharmaceuticals
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Therapeutic Devices
Drug Delivery
Acquirer
Primary Office
  • 110 Allen Road
  • Bernards, NJ 07938
  • United States

+1 (908) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Reliant Pharmaceuticals’s full profile, request a free trial.

Reliant Pharmaceuticals Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
9. IPO 21-Nov-2007 $305M 00.000 Cancelled Clinical Trials - Phase 3
8. Merger/Acquisition 01-Nov-2007 00.000 00000 00.000 Completed Clinical Trials - Phase 3
7. IPO 30-May-2005 00000 00.000 Cancelled Clinical Trials - Phase 3
6. Secondary Transaction - Private 00000 Completed
5. Later Stage VC (Series D) 16-Dec-2003 00000 00000 00000 Completed Generating Revenue
4. Merger/Acquisition 22-Mar-2002 00000 00000 Cancelled Generating Revenue
3. Later Stage VC (Series C) 18-Dec-2001 00000 00000 00000 Completed Generating Revenue
2. Early Stage VC (Series B) 01-Jul-2001 $135M $139M 00000 Completed Generating Revenue
1. Early Stage VC (Series A) 01-Aug-1999 $4.25M $4.25M Completed Product Development
To view this company’s complete deal history including valuation and funding, request access »

Reliant Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series D 00,000,000 00.000000 0.00 000 000 00 000 00.000
Series C 0,000,000 00.000000 0.00 000 000 00 000 00.000
Series B 14,250,000 $0.010000 8.5% $10 $10 1x $10 31.99%
Series A 425,000 $0.010000 8.5% $10 $10 1x $10 1.01%
To view this company’s complete Cap Table, request access »

Reliant Pharmaceuticals Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alkermes Corporation Minority 000 0000 000000 0
Barron Partners PE/Buyout Minority 000 0000 000000 0
Bay City Capital Venture Capital Minority 000 0000 000000 0
Individual Investor Angel (individual) Minority 000 0000 000000 0
Invemed Associates Investment Bank Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Reliant Pharmaceuticals Executive Team (4)

Name Title Board
Seat
Contact
Info
Ernest Mario Chairman & Chief Executive Officer
Larry Gyenes Chief Financial Officer
Mark Hoplamazian Vice President & Assistant Secretary

1 Former Executive

You’re viewing 3 of 4 executives. Get the full list »

Reliant Pharmaceuticals Board Members (2)

Name Representing Role Since Contact
Info
Ernest Mario Reliant Pharmaceuticals Chairman & Chief Executive Officer 000 0000

1 Former Board Member

You’re viewing 1 of 2 board members. Get the full list »